INTRAVITREAL BEVACIZUMAB VERSUS COMBINED INTRAVITREAL BEVACIZUMAB AND TRIAMCINOLONE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

• DOI: 10.1097/iae.0b013e31820d58f2
• Publication Date: 2011-05-07T07:22:53Z
• Authors: Hamid Ahmadieh; Ramin Taei; Mohammad Riazi-Es...; Niloufar Piri; Mansour Homayouni; Narsis Daftarian; Mehdi Yaseri
• Keywords: Aged, 80 and over; Male; Vascular Endothelial Growth Factor A; Angiogenesis Inhibitors; Middle Aged; Antibodies, Monoclonal, Humanized; Triamcinolone Acetonide; 3. Good health; Bevacizumab; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Intravitreal Injections; Retreatment; Humans; Drug Therapy, Combination; Female; Prospective Studies; Fluorescein Angiography; Glucocorticoids; Tomography, Optical Coherence; Aged; Follow-Up Studies

To determine whether combined intravitreal bevacizumab (IVB) and triamcinolone (IVT) is more effective than IVB alone in neovascular age-related macular degeneration.This was a prospective, randomized clinical trial performed at two centers. Eligible eyes were assigned randomly to one of the study arms. In group, 3 consecutive injections 1.25 mg given 6 weeks apart, while IVB/IVT first triple with 2 IVB. A fourth injected demonstrating active choroidal neovascularization Week 24.Sixty 55 groups, respectively. Best-corrected visual acuity improved, central thickness reduced significantly both groups all time points. Visual improvement pronounced group compared (8.5 ± 14.4 vs. 3.8 8.9 letters, P = 0.04) 12 (11.8 16.6 6.2 10.8 0.03) after initiation therapy. However, there no significant difference 24 (11.3 17.2 letters 8.7 15.6 0.40). The showed less need for injection (34.5% 53.3% respectively, 0.04).Mandated therapy improved best-corrected decreased degeneration. addition low-dose IVT temporarily increased therapeutic efficacy early postinjection period resulted fewer requirements repeat months; however, final levels comparable groups.